Viewing nowPregabalin 150mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

MFDS item code 201109293 · Notified 2011.10.31 · Insurance code 657305740
Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures in epilepsy
This medication is used to alleviate peripheral and central neuropathic pain in adults. It can also be used as an adjunct for partial seizures in epilepsy, whether or not accompanied by secondary general symptoms. Additionally, it is effective for treating pain due to fibromyalgia. In summary, it is used for the treatment of peripheral and central neuropathic pain, adjunctive therapy for partial seizures in epilepsy, and for fibromyalgia treatment.
This medicine is administered orally as pregabalin, in 2 divided doses per day, regardless of food. Since this medicine is excreted mainly by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg per day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased to 225 mg twice daily (450 mg per day) within 1 week. Clinical studies were also conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted mainly by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration Initial dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified under Administration. b: Supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.
7. Pediatric and adolescent patients Administration is not recommended because there are insufficient data on safety and efficacy in children under 12 years of age and adolescent patients aged 12 to 17 years.
This medication may increase the risk of suicidal thoughts or behavior, so one should monitor for mood changes or abnormal behavior while taking it. It should not be taken by individuals with hypersensitivity to the drug or with certain genetic disorders such as lactose intolerance. Diabetic patients should be cautious, as weight gain may require adjustments in diabetes control medications. If symptoms of angioedema occur, discontinue use immediately and consult a healthcare professional. Elderly patients should be particularly careful at the beginning of treatment due to the risk of dizziness or drowsiness causing falls or injuries. Blurred vision or changes in eyesight may occur, and if these symptoms appear, discontinuation of the medication should be considered. Sudden discontinuation of this medication may result in withdrawal symptoms such as insomnia, headache, and anxiety, so it should be tapered off gradually in consultation with a healthcare professional. Patients with a history of mental illness or substance abuse should be especially cautious due to the risk of drug misuse. Patients with reduced renal function may require dosage adjustments. Patients with heart disease should be aware of the risk of congestive heart failure. If taken in conjunction with opioid analgesics, side effects due to central nervous system depression may be exacerbated. Patients with impaired respiratory function or elderly individuals may require dosing adjustments due to the risk of severe respiratory depression. Pregnant women, especially in the first trimester, should consult a healthcare provider before use due to the risk of fetal malformations. Breastfeeding women should consider stopping breastfeeding or the medication, as this drug may be passed to breast milk. For activities such as driving or operating machinery, it is advisable to avoid until any dizziness or drowsiness has resolved after taking this medication. Severe skin reactions may rarely occur, so if any unusual symptoms such as rashes or swelling develop, discontinue use immediately and inform a healthcare provider. In the case of an overdose, symptoms such as drowsiness, confusion, depression, and seizures may occur, necessitating immediate medical attention, and blood dialysis may be required if necessary. This medication should be stored out of the reach of children and not transferred to other containers for safety.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is best to maintain a storage temperature between 15 and 30 degrees Celsius.
A hard capsule with a white or light yellow powder inside, with a white cap and body.
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.